Onrigin FDA Approval Status
FDA Approved: No
Brand name: Onrigin
Generic name: laromustine
Dosage form: Injection
Company: Vion Pharmaceuticals, Inc.
Treatment for: Acute Myeloid Leukemia
Onrigin (laromustine), formerly known as Cloretazine (VNP40101M), is a novel alkylating agent in development for remission induction treatment for patients sixty years of age or older with de novo poor-risk acute myeloid leukemia (AML).
Development Timeline for Onrigin
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.